^○Yosuke Tanaka¹, Fumiko Chiwaki², Shinya Kojima¹, Masahito Kawazu¹, Masayuki Komatsu², Toshihide Ueno¹, Satoshi Inoue¹, Shigeki Sekine³, Keisuke Matsusaki⁴, Hiromichi Matsushita⁵, Narikazu Boku⁶, Yae Kanai⁷, Yasushi Yatabe³, Hiroki Sasaki², Hiroyuki Mano¹ (1.Division of Cellular Signaling, National Cancer Center Research Institute, 2.Department of Translational Oncology, National Cancer Center Research Institute, 3.Department of Diagnostic Pathology, National Cancer Center Hospital, 4.Kanamecho Hospital, 5.Department of Laboratory Medicine, National Cancer Center Hospital, 6.Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 7.Department of Pathology, Keio University School of Medicine)

^○Hideyuki Hayashi¹, Shigeki Tanishima², Kaori Mochida¹, Tomoka Fujikura¹, Sachiko Hagiwara¹, Emmy Yanagita¹, Hiroshi Yamada¹, Ryutaro Kawano¹, Kohei Nakamura¹, Marin Ishikawa¹, Yasutaka Kato¹, Eriko Aimono¹, Mitsuho Imai¹, Arisa Ueki¹, Hiroshi Nishihara¹ (1.Genomics Unit, Keio Cancer Center, Keio University School of Medicine, 2.Department of Biomedical Informatics Development, Mitsubishi Space Software Co., Ltd)

^○Shigeki Nanjo^1,2, Ross Okimoto², Seiji Yano¹, Trever Bivona² (1.Division of Medical Oncology, Kanazawa University Cancer Research Institute, 2.Division of Hematology/ Oncology, University of California San Francisco)

^○Shunji Takahashi¹, Nobumasa Mizuno², Kosei Hasegawa³, Koji Matsumoto⁴, Shirong Han⁵, Tsutomu Takatsuki⁶, Fan Jin⁷, Kazuhiko Nakagawa⁸ (1.Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 2.Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan, 3.Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan, 4.Division of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan, 5.Biostatistics and Research Decision Sciences, MSD K.K, Tokyo, Japan, 6.Clinical Development, MSD K.K, Tokyo, Japan, 7.Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA, 8.Department of Medical Oncology, Kindai University Hospital, Osaka, Japan)

^○Santiago Ponce Aix¹, Emiliano Calvo², Victor Moreno³, Guzman Alonso⁴, Andres Cervantes⁵, Suresh S. Ramalingam⁶, Jose Trigo⁷, Patricia Lorusso⁸, Muhammad Furqan⁹, Daniel Cho¹⁰, Alexander Muik¹¹, Eleni Lagkadinou¹¹, Özlem Türeci¹¹, Nora Pencheva¹², Ulf Forssmann¹¹, Ugur Sahin¹¹, Tahamtan Ahmadi¹³, Brandon Higgs¹³, Maria Jure-Kunkel¹³, Ignacio Melero¹⁴ (1.Hospital Universitario 12 de Octubre, Madrid, Spain, 2.START Madrid-CIOCC, Madrid, Spain, 3.START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain, 4.Vall d’Hebron Institute of Oncology, Barcelona, Spain, 5.University Hospital of Valencia, Valencia, Spain, 6.Winship Cancer Institute of Emory University, Atlanta, GA, USA, 7.Hospital Universitario Virgen de la Victoria, Málaga, Spain, 8.Yale Cancer Center, New Haven, CT, USA, 9.University of Iowa, Iowa City, IA, USA, 10.NYU Langone Health Tisch Hospital, New York, NY, USA, 11.BioNTech SE, Mainz, Germany, 12.Genmab A/S, Copenhagen, Denmark, 13.Genmab, Princeton, NJ, USA, 14.Clinica Universidad de Navarra, Pamplona, Spain)

^○Gaurav Bajaj⁵, Fereshteh Nazari², Marc Presler², Craig Thalhauser⁵, Ulf Forssmann³, Maria Jure-Kunkel⁵, Alexander Muik⁴, Eleni Lagkadinou⁴, Özlem Türeci⁴, Uğur Şahin⁴, Tahamtan Ahmadi⁵, Manish Gupta⁵ (1.Genmab, 2.Applied BioMath LLC, Concord, MA, USA, 3.Genmab A/S, Copenhagen, Denmark, 4.BioNTech SE, Mainz, Germany, 5.Genmab, Princeton, NJ, USA)